4DMedical signs distribution agreement with Philips for U.S. market

4DMedical Limited (ASX:4DX) has announced the signing of a distribution agreement appointing Philips as an authorized reseller across the United States. The 5-year agreement grants Philips exclusive distribution rights to 4DMedical's suite of products with U.S. government customers and non-exclusive rights with all other U.S. customers.

Executive commentary on the agreement with Philips

The agreement with Philips sets a new benchmark in lung health and transforms our ability to deliver our technology to patients and their doctors. Together, Philips and 4DMedical will deliver lung function analyses for all lung disorders, including unexplained dyspnoea (shortness of breath), asthma, COPD, and interstitial lung disease (ILD). This ongoing collaboration is a pivotal strategy to provide advanced care and support for those who have bravely served.

Summary of the distribution agreement and market outlook

4DMedical (ASX:4DX) has signed a 5-year distribution agreement with Philips, granting exclusive distribution rights to Philips for its suite of products with U.S. government customers and non-exclusive rights with all other U.S. customers. The agreement leverages Philips' existing commercial partnerships with the VA and the Department of Defense, creating a transformative commercial pathway for 4DMedical's product suite in the U.S. The company aims to address significant health challenges faced by Veterans due to military toxic exposures and provide advanced care and support. The market opportunity in the U.S. is substantial, with a large number of Thoracic CT scans performed annually, presenting a compelling mechanism for 4DMedical and Philips to leverage this opportunity. The signing of this agreement marks a significant milestone for 4DMedical's commercialization success and its mission to improve healthcare for all.